Clinical Trials Archive - Page 4 of 16

recruiting PHASE2 Oncology NCT05489211

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Sponsor: AstraZeneca

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06997497

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE2 Oncology NCT06692959

A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer

The aim of Neo-POLEM is to determine the rate of Major Pathological Response (MPR) of

Sponsor: University of Southampton

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT07284849

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal…

Sponsor: Incyte Corporation

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06136624

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT05939414

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to…

Sponsor: Novartis Pharmaceuticals

View Trial ClinicalTrials.gov ↗

recruiting NA Oncology NCT06638541

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on…

Sponsor: Royal Marsden NHS Foundation Trust

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06629779

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone…

Sponsor: Pfizer

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Oncology NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

recruiting PHASE1 Oncology NCT06353386

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal…

Sponsor: Merck Sharp & Dohme LLC

View Trial ClinicalTrials.gov ↗

Clinical Trials

Join 10,000+ UK Clinicians